Regeneron Pharmaceuticals, Inc. (REGN)
957.91
+5.51
(+0.58%)
USD |
NASDAQ |
Nov 17, 16:00
957.00
-0.91
(-0.09%)
After-Hours: 20:00
Regeneron Pharmaceuticals Price : 957.91 for Nov. 17, 2026
Price Chart
Historical Price Data
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Nov 16, 2026 | 963.32 | 972.24 | 947.81 | 952.40 | 700862.0 |
| Nov 13, 2026 | 952.47 | 961.94 | 942.00 | 955.47 | 1.166M |
| Nov 12, 2026 | 972.30 | 981.55 | 944.71 | 951.19 | 1.211M |
| Nov 11, 2026 | 904.99 | 961.98 | 898.29 | 959.41 | 1.234M |
| Nov 10, 2026 | 915.34 | 919.72 | 905.38 | 916.06 | 517080.0 |
| Nov 09, 2026 | 922.35 | 933.36 | 901.07 | 919.96 | 856756.0 |
| Nov 06, 2026 | 887.22 | 911.64 | 887.04 | 904.35 | 1.123M |
| Nov 05, 2026 | 938.51 | 948.11 | 901.53 | 902.90 | 1.407M |
| Nov 04, 2026 | 989.90 | 991.73 | 927.42 | 930.67 | 1.395M |
| Nov 03, 2026 | 956.28 | 975.48 | 953.00 | 973.36 | 1.200M |
| Nov 02, 2026 | 927.22 | 974.00 | 927.00 | 961.26 | 1.661M |
| Oct 30, 2026 | 869.43 | 935.35 | 839.08 | 927.89 | 2.871M |
| Oct 29, 2026 | 826.14 | 828.19 | 811.63 | 818.77 | 789303.0 |
| Oct 28, 2026 | 807.06 | 821.16 | 802.20 | 813.27 | 536498.0 |
| Oct 27, 2026 | 807.67 | 816.14 | 804.05 | 816.10 | 726152.0 |
| Oct 26, 2026 | 812.31 | 817.17 | 796.61 | 807.67 | 423958.0 |
| Oct 23, 2026 | 819.09 | 819.09 | 801.22 | 805.02 | 527739.0 |
| Oct 22, 2026 | 809.01 | 825.52 | 800.00 | 819.09 | 852594.0 |
| Oct 21, 2026 | 806.74 | 813.86 | 800.24 | 805.67 | 581051.0 |
| Oct 20, 2026 | 793.85 | 807.86 | 789.69 | 807.48 | 623400.0 |
| Oct 19, 2026 | 792.59 | 800.00 | 780.83 | 782.04 | 489580.0 |
| Oct 16, 2026 | 803.01 | 805.68 | 787.32 | 790.74 | 653725.0 |
| Oct 15, 2026 | 802.33 | 809.49 | 792.58 | 796.34 | 798909.0 |
| Oct 14, 2026 | 758.16 | 781.84 | 755.21 | 778.36 | 879091.0 |
| Oct 13, 2026 | 762.48 | 765.60 | 743.57 | 753.12 | 629557.0 |
Price Definition
The price of a security measures the cost to purchase 1 share of a security. For a company, price can be multiplied by shares outstanding to find the market capitalization (value of the company).
Price Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Price Benchmarks
| Gilead Sciences, Inc. | 170.43 |
| AbbVie, Inc. | 292.80 |
| Vertex Pharmaceuticals, Inc. | 534.04 |
| Amgen, Inc. | 457.91 |
| Alnylam Pharmaceuticals, Inc. | 156.54 |
Price Related Metrics
| PE Ratio | 21.15 |
| PS Ratio | 6.049 |
| PEG Ratio | 2.504 |
| Price to Book Value | 2.957 |
| Price to Free Cash Flow | 28.17 |
| Earnings Yield | 4.73% |
| Market Cap | 99.05B |
| PEGY Ratio | 2.394 |
| Operating PE Ratio | 19.91 |
| Normalized PE Ratio | 19.62 |